Zahid Mohammad Faizan, Mehdi Mohammad Qasim, Ali Natasha
Temple University Hospital, Philadelphia, PA, USA.
Medical College, Aga Khan University, Karachi, Pakistan.
Hematol Transfus Cell Ther. 2019 Apr-Jun;41(2):134-138. doi: 10.1016/j.htct.2018.08.006. Epub 2018 Dec 31.
Hairy cell leukemia is an uncommon, indolent B-cell lymphoproliferative disorder. Therapy with cladribine (2-chlorodeoxyadenosine) is able to induce complete remission (CR) in the majority of patients after a single course of treatment. We report the outcomes of patients treated at Aga Khan University Hospital, Karachi, Pakistan.
This was a retrospective review. Medical records of patients were used to collect data.
A total of 21 patients with hairy cell leukemia were treated with cladribine. All patients achieved an initial CR. Four patients (19%) required hospitalization and therapy for neutropenic fever. Six patients (29%) relapsed at a median of 48 months. All 6 patients were treated for relapse, out of which 4 achieved CR, 1 had partial response and 1 had refractory disease. The overall survival rate was 90.5%, with a median follow-up of 35 months.
A single course of cladribine is able to induce CR in a vast majority of patients. Unfortunately, relapse is not uncommon. Patients who relapse can be successfully retreated with cladribine. Cladribine has impressive efficacy and a favorable acute and long-term toxicity profile when administered to patients with HCL.
毛细胞白血病是一种罕见的惰性B细胞淋巴增殖性疾病。使用克拉屈滨（2-氯脱氧腺苷）治疗能够使大多数患者在一个疗程后达到完全缓解（CR）。我们报告了在巴基斯坦卡拉奇阿迦汗大学医院接受治疗的患者的治疗结果。
这是一项回顾性研究。通过患者的病历收集数据。
共有21例毛细胞白血病患者接受了克拉屈滨治疗。所有患者均达到初始CR。4例患者（19%）因中性粒细胞减少性发热需要住院治疗。6例患者（29%）复发，中位复发时间为48个月。所有6例复发患者均接受了复发治疗，其中4例达到CR，1例部分缓解，1例疾病难治。总生存率为90.5%，中位随访时间为35个月。
一个疗程的克拉屈滨能够使绝大多数患者达到CR。不幸的是，复发并不罕见。复发患者可以成功地用克拉屈滨再次治疗。当给毛细胞白血病患者使用克拉屈滨时，其具有令人印象深刻的疗效以及良好的急性和长期毒性特征。
